Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 4/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | CALML3 | P27482 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SDHA | P31040 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 4/20 | 0.43 |
| ▸ | F10 | P00742 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5707298 | 1.00 | ABCB11 (0.45) | ABCB11MAOAMAOBCALML3LMNA | |
| Hydrochloric Acid SCHEMBL1176888 | 0.99 | ABCB11 (0.45) | ABCB11MAOAMAOBCALML3LMNA | |
| Hydrochloric Acid SCHEMBL1176889 | 0.99 | ABCB11 (0.45) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL8703285 | 0.91 | MAOA (0.46) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL8871678 | 0.91 | MAOA (0.46) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL9028107 | 0.88 | ABCB11 (0.44) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL8871159 | 0.86 | F10 (0.52) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL8701633 | 0.86 | F10 (0.52) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL8489161 | 0.86 | MAOA (0.55) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL8489164 | 0.86 | MAOA (0.55) | ABCB11MAOAMAOBCALML3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795601-B2 | Compositions and methods for cancer treatment | BIOVISTA, INC. (US) | 2017-10-24 | — | — | US | claimed |
| US-20130259800-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BIOVISTA, INC. (US) | 2013-10-03 | — | — | US | claimed |
| WO-2012082992-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BIOVISTA, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| EP-1471890-B1 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORP (US) | 2006-09-27 | — | — | EP | claimed |
| EP-1575618-B1 | DISPERSIBLE PHARMACEUTICAL COMPOSITIONS | PHARMACIA & UPJOHN CO LLC (US) | 2006-08-16 | — | — | EP | claimed |
| EP-1311296-B1 | SOLUTION OF AN OXAZOLIDINONE ANTIBIOTIC DRUG | PHARMACIA CORP (US) | 2005-12-14 | — | — | EP | claimed |
| EP-1575618-A2 | DISPERSIBLE PHARMACEUTICAL COMPOSITIONS | Pharmacia & Upjohn Company LLC (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1096934-B1 | OXAZOLIDINONES TO TREAT EYE INFECTIONS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2004060345-A2 | DISPERSIBLE PHARMACEUTICAL COMPOSITIONS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-07-22 | — | — | WO | claimed |
| EP-1032386-B1 | USE OF OXAZOLIDINONE DERIVATIVES FOR TREATING ARTHRITIS | UPJOHN CO (US) | 2003-02-26 | — | — | EP | claimed |
| EP-1083900-B1 | USE OF OF OXAZOLIDINONES FOR THE PREPARATION OF A MEDICAMENT FOR TRANSDERMAL DELIVERY | UPJOHN CO (US) | 2002-07-17 | — | — | EP | claimed |
| EP-1032386-A1 | USE OF OXAZOLIDINONE DERIVATITIVES FOR TREATING PSORIASIS, ARTHRITIS AND REDUCING THE TOXICITY OF CANCER CHEMOTHERAPY | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-06 | — | — | EP | claimed |
| US-6040306-A | Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy | PHARMACIA & UPJOHN COMPANY | 2000-03-21 | — | — | US | claimed |
| WO-1999025344-A1 | USE OF OXAZOLIDINONE DERIVATIVES FOR TREATING PSORIASIS, ARTHRITIS AND REDUCING THE TOXICITY OF CANCER CHEMOTHERAPY | PHARMACIA & UPJOHN COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
| US-9795601-B2 | Compositions and methods for cancer treatment | BIOVISTA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20130259800-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BIOVISTA, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2012082992-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BIOVISTA, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-1032386-B1 | USE OF OXAZOLIDINONE DERIVATIVES FOR TREATING ARTHRITIS | UPJOHN CO (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020009483-A1 | TOPICAL ADMINISTRATION OF OXAZOLIDINONES FOR TRANSDERMAL DELIVERY | PHARMACIA & UPJOHN COMPANY | 2002-01-24 | — | — | US | disclosed |
| US-6040306-A | Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy | PHARMACIA & UPJOHN COMPANY | 2000-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130259800-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BRAF, ERBB3, ERBB2 | ABCB11 2201/4885MAOA 554/4885MAOB 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.